Recent advances in research on human enterovirus 71

Future Virology

Volumn 5, Issue 4, 2010, Pages 453-468

  Bek, Emily J ^a   McMinn, Peter C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

hand, foot and mouth disease; human enterovirus 71; internal ribosome entry site; picornavirus; RNA dependent RNA polymerase; viral encephalitis

Indexed keywords

CLEAVAGE STIMULATION FACTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACTINOMYCIN; HLA A ANTIGEN; IMMUNOGLOBULIN; INACTIVATED VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPYRIMIDINE TRACT BINDING PROTEIN; RIBAVIRIN; STEROID; VIRUS RECEPTOR;

5' UNTRANSLATED REGION; ASEPTIC MENINGITIS; ATAXIA; CELL STRAIN CACO 2; CELL STRAIN COS7; CELLULAR IMMUNITY; CRANIAL NERVE PARALYSIS; CYANOSIS; DISEASE PREDISPOSITION; DRUG EFFICACY; ENCEPHALITIS; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; EPIDEMIC; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FLACCID PARALYSIS; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HAPLOTYPE; HELA CELL; HERPANGINA; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; LUNG EDEMA; MYOCLONUS; NONHUMAN; NYSTAGMUS; PATHOGENESIS; PHENOTYPE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SCID MOUSE; SOUTHEAST ASIA; SPECIES COMPARISON; TACHYCARDIA; TACHYPNEA; TEMPERATURE SENSITIVITY; TREMOR; VERO CELL; VIRUS ENCEPHALITIS; VIRUS ENTRY; VIRUS MUTATION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

ANIMALIA; ENTEROVIRUS; HUMAN ENTEROVIRUS 71; PICORNAVIRIDAE; POLIOVIRUS;

EID: 77954895839     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.22     Document Type: Review

References (180)

1. McMinn P: An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMSMicrobiol. Rev. 26(1), 91-107 (2002).
2. Lin J-Y, Li M-L, Shih S-R: Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucl. Acids Res. 37(1), 47-59 (2009).
3. Thompson SR, Sarnow P: Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology 315(1), 259-266 (2003).
4. Bedard KM, Semler BL: Regulation of picornavirus gene expression. Microbes Infect. 6(7), 702-713 (2004).
5. Schmidt NJ, Lennette EH, Ho HH: An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 129(3), 304-309 (1974).
6. Cardosa MJ, Perera D, Brown BA et al.: Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 9(4), 461-468 (2003).
7. Chang L-Y, Chang IS, Chen W-J et al.: HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics 122(6), 1271-1276 (2008).
8. Ho H-Y, Cheng M-L, Weng S-F et al.: Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J. Gen. Virol. 89(9), 2080-2089 (2008).
9. Yang KD, Yang MY, Li CC et al.: Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J. Infect. Dis. 183(6), 850-856 (2001).
10. Wang S-M, Lei H-Y, Huang K-J et al.: Pathogenesis of Enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J. Infect. Dis. 188(4), 564-570 (2003).
11. Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, Yang KD: Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. ActaPaediatr. 91(6), 632-635 (2002).
12. Lin T-Y, Hsia S-H, Huang Y-C, Wu C-T, Chang L-Y: Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin. Infect. Dis. 36(3), 269-274 (2003).
13. van der Sanden S, Koopmans M, Uslu G, van der Avoort H; on behalf of the Dutch Working Group for Clinical V: Epidemiology of enterovirus 71 in The Netherlands, 1963 to 2008. J. Clin. Microbiol. 47(9), 2826-2833 (2009).
14. Yoke-Fun C, AbuBakar S: Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol. 6(1), 74 (2006).
15. Chen G-W, Hsiung C, Chyn J-L, Shih S-R, Wen C-C, Chang IS: Revealing molecular targets for enterovirus type 71 detection by profile hidden Markov models. Virus Genes 31(3), 337-347 (2005).
16. Huang S-W, Hsu Y-W, Smith DJ et al.: Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J. Clin. Microbiol. 47(11), 3653-3662 (2009).
17. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA: Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J. Virol. 73(12), 9969-9975 (1999).
18. Deshpande JM, Nadkarni SS, Francis PP: Enterovirus 71 isolated from a case of acute flaccid paralysis in India represents a new genotype. Curr. Sci. 84(10), 1350-1353 (2003).
19. AbuBakar S SI-C, Yusof J, Lim MK, Misbah S, MatRahim N, Hooi P-S: Enterovirus 71 outbreak, Brunei. Emerg. Infect. Dis. 15(1), 79-82 (2009).
20. Bible JM, Iturriza-Gomara M, Megson B et al.: Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J. Clin. Microbiol. 46(10), 3192-3200 (2008).
21. Bible JM, Pantelidis P, Chan PKS, Tong CYW: Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev. Med. Virol. 17(6), 371-379 (2007).
22. Iwai M, Masaki A, Hasegawa S et at.: Genetic changes of Coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Japan J. Infect. Dis. 65(4), 254-259 (2009).
23. Lin K-H, Hwang K-P, Ke G-M et al.: Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J. Med. Virol. 78(2), 254-262 (2006).
24. McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, Cardosa MJ: Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J. Virol. 75(16), 7732-7738 (2001).
25. Sanders SA, Herrero LJ, McPhie K et al.: Molecular epidemiology of enterovirus 71 over two decades in an Australian urban community. Arch. Virol. 151(5), 1003-1013 (2006).
26. Zhang Y, Tan X-J, Wang H-Y et al.: An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J. Clin. Virol. 44(4), 262-267 (2009).
27. Fujimoto T, Chikahira M, Yoshida S et al.: Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 46(9), 621-627 (2002).
28. Herrero LJ, Lee CSM, Hurrelbrink RJ, Chua BH, Chua KB, McMinn PC: Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997-2000. Arch. Virol. 148(7), 1369-1385 (2003).
29. Shimizu H, Utama A, Onnimala N et al.: Molecular epidemiology of enterovirus 71 infection in the western Pacific Region. Pediatr. Int. 46(2), 231-235 (2004).
30. Solomon TA, Willison HB: Infectious causes of acute flaccid paralysis. Curr. Opn. Infect. Dis. 16(5), 375-381 (2003).
31. Wits0 E, Palacios G, R0nningen KS et al.: Asymptomatic circulation of HEV71 in Norway. Virus Res. 123(1), 19-29 (2007).
32. Ho M, Chen ER, Hsu KH et al.: An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341(13), 929-935 (1999).
33. Singh S, Poh CL, Chow VTK: Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore (2000). Microbiol.. Immunol. 46(11), 801-808 (2002).
34. Wang J-R, Tuan Y-C, Tsai H-P, Yan J-J, Liu C-C, Su I-J: Change of major genotype of Enterovirus 71 in outbreaks of hand-foot-and- mouth disease in Taiwan between 1998 and 2000. J. Clin. Microbiol. 40(1), 10-15 (2002).
35. Hayward JC, Gillespie SM, Kaplan KM et al.: Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Ped. Infect. Dis. J. 8(9), 611-615 (1989).
36. Nagy G, Takatsy S, Kukan E: Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch. Virol. 71(3), 217-227 (1982).
37. Chonmaitree T, Menegus MA, Schervish- Swierkosz EM, Schwalenstocker E: Enterovirus 71 infection: report of an outbreak with two cases of paralysis and a review of the literature. Pediatrics 67(4), 489-493 (1981).
38. Samuda GM, Chang WK, Yeung CY, Tang PS: Monoplegia caused by enterovirus 71: an outbreak in Hong Kong. Ped. Infect. Dis. J. 6(2), 206-208 (1987).
39. Lum LCS, Wong KT, Lam SK et al.: Fatal enterovirus 71 encephalomyelitis. J. Ped. 133(6), 795-798 (1998).
40. Melnick JL: Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev. Infect. Dis. 6, S387-S390 (1984).
41. Chumakov M, Voroshilova M, Shindarov L: Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch. Virol. 60(3-4), 329-340 (1979).
42. Wang S-M, Liu C-C, Tseng H-W et al.: Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin. Infect. Dis. 29(1), 184-190 (1999).
43. Shen WC, Tsai CH, Chiu HH, Chow KC: MRI of enterovirus 71 myelitis with monoplegia. Neuroradiology 42(2), 124-127 (2000).
44. Modlin J: Poliomyelitis and poliovirus immunization. In: Human Enterovirus Infections. Rotbart H (Ed.). ASM Press, Washington, DC, USA 196-220 (1995).
45. Shindarov LM, Chumakov MP, Voroshilova MK: Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J. Hyg. Epidemiol. Microbiol. Immunol. 23(3), 284-295 (1979).
46. McMinn P, Stratov I, Nagarajan L, Davis S: Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin. Infect. Dis. 32(2), 236-242 (2001).
47. Samuda GM, Chang W-K, Yeung C-Y, Tang P-S: Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Ped. Infect. Dis. J. 6(2), 206-208 (1987).
48. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF: Neurologic complications in children with enterovirus 71 infection. N. Engl. J. Med. 341(13), 936-942 (1999).
49. Chen CY, Chang YC, Huang CC, Lui CC, Lee KW, Huang SC: Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. Am. J. Neuroradiol 22(1), 200-205 (2001).
50. Hsueh C, Jung SM, Shih SR et al.: Acute encephalomyelitis during an outbreak of enterovirus type 71 infection in Taiwan: report of an autopsy case with pathologic, immunofluorescence, and molecular studies. Modern Pathol. 13(11), 1200-1205 (2000).
51. Chan K, Goh KT, Chong CY, Teo ES, Lau G, Ling AE: Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 9(1), 78-85 (2003).
52. Landry ML, Fonseca SNS, Cohen S, Bogue CW: Fatal enterovirus type 71 infection: rapid detection and diagnostic pitfalls. Ped. Infect. Dis. J. 14(12), 1095-1100 (1995).
53. Chang LY, Lin TY, Hsu KH et al.: Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 354(9191), 1682-1686.
54. Ng DKK, Law AKW, Cherk SWW, Mak KL: First fatal case of enterovirus 71 infection in Hong Kong. Hong Kong Med. J. 7(2), 193-196 (2001).
55. Chan L, Parashar U, Lye M et al.: Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin. Infect. Dis. 31(3), 678-683 (2002).
56. Ho M: Enterovirus 71: the virus, its infections and outbreaks. J. Microbiol. Immunol. Infect. 33(4), 205-216 (2000).
57. Prager P, Nolan M, Andrews IP, Williams GD: Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. Ped. Crit. Care Med. 4(3), 377-381 (2003).
58. Chang L-Y, Huang L-M, Gau SS-F et al.: Neurodevelopment and cognition in children after enterovirus 71 infection. N. Engl. J. Med. 356(12), 1226-1234 (2007).
59. Hsia SH, Wu CT, Chang JJ et al.: Predictors of unfavorable outcomes in enterovirus 71-related cardiopulmonary failure in children. Ped. Infect. Dis. J. 24(4), 331-334 (2005).
60. Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC: Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet 354(9183), 987-991 (1999).
61. Wong KT, Chua KB, Lam SK: Immunohistochemical detection of infected neurons as a rapid diagnosis of enterovirus 71 encephalomyelitis. Ann. Neurol. 45(2), 271-272 (1999).
62. Yan J-J, Wang J-R, Liu C-C, Yang H-B, Su I-J: An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J. Clin. Virol. 17(1), 13-22 (2000).
63. Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, Chen SH: Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J. Virol. 83(13), 6477-6483 (2009).
64. Hashimoto I, Hagiwara A, Kodama H: Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Brief report. Arch. Virol. 56(3), 257-261 (1978).
65. Hagiwara A, Yoneyama T, Takami S, Hashimoto I: Genetic and phenotypic characteristics of enterovirus 71 isolates from patients with encephalitis and with hand, foot and mouth disease. Arch. Virol. 79(3-4), 273-283 (1984).
66. Nagata N, Shimizu H, Ami Y et al.: Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J. Med. Virol. 67(2), 207-216 (2002).
67. Nagata N, Iwasaki T, Ami Y et al.: Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J. Gen. Virol. 85(10), 2981-2989 (2004).
68. Yamayoshi S, Yamashita Y, Li J et al.: Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 15(7), 798-801 (2009).
69. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H: Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 15(7), 794-797 (2009).
70. Patel KP, Bergelson JM: Receptors identified for hand, foot and mouth virus. Nat. Med. 15(7), 728-729 (2009).
71. Ohba K, Ryo A, Dewan MZ et al.: Follicular dendritic cells activate HIV-1 replication in monocytes/macrophages through a juxtacrin mechanism mediated by P-selectin glycoprotein ligand 1. J. Immunol. 183(1), 524-532 (2009).
72. Klopocki AG, Yago T, Mehta P et Replacing a lectin domain residue in L-selectin enhances binding to P-selectin glycoprotein ligand-1 but not to 6-sulfo-sialyl lewis x. J. Biol. Chem. 283(17), 11493-11500 (2008).
73. Eckhardt ERM, Cai L, Shetty S et al.: High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif. J. Biol. Chem. 281(7), 4348-4353 (2006).
74. Eckhardt ERM, Cai L, Sun B, Webb NR, van der Westhuyzen DR: High density lipoprotein uptake by scavenger receptor SR-BII. J. Biol. Chem. 279(14), 14372-14381 (2004).
75. Grove J, Huby T, Stamataki Z et al.: Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J. Virol. 81(7), 3162-3169 (2007).
76. Needleman SB, Wunsch CD: A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48(3), 443-453 (1970).
77. Wilkins MR, Gasteiger E, Gooley AA et al.: High-throughput mass spectrometric discovery of protein post-translational modifications. J. Mol. Biol. 289(3), 645-657 (1999).
78. Silver DL: SR-BI and protein-protein interactions in hepatic high density lipoprotein metabolism. Rev. Endocr. Metab. Disord. 5(4), 327-333 (2004).
79. Rhainds D, Brissette L: The role of scavenger receptor class B type I (SR-BI) in lipid trafficking: defining the rules for lipid traders. Int. J. Biochem. Cell Biol. 36(1), 39-77 (2004).
80. Lin Y-W, Wang S-W, Tung Y-Y, Chen S-H: Enterovirus 71 infection of human dendritic cells. Exp. Biol. Med. 234(10), 1166-1173 (2009).
81. Yang B, Chuang H, Yang K: Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol. J. 6(1), 141 (2009).
82. Lee JC, Wu TY, Huang CF, Yang FM, Shih SR, Hsu JTA: High-efficiency protein expression mediated by enterovirus 71 internal ribosome entry site. Biotechnol. Bioeng. 90(5), 656-662 (2005).
83. Pestova TV, Shatsky IN, Fletcher SP, Jackson RJ, Hellen CUT: A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev. 12(1), 67-83 (1998).
84. Wu T-Y, Hsieh C-C, Hong J-J, Chen C-Y, Tsai Y-S: IRSS: a web-based tool for automatic layout and analysis of IRES secondary structure prediction and searching system in silico. BMC Bioinformatics 10(1), 160 (2009).
85. Weng KF, Li ML, Hung CT, Shih SR: Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoSPathog. 5(9), e1000593 (2009).
86. Bonderoff JM, LaRey JL, Lloyd RE: Cleavage of poly(A)-binding protein by poliovirus 3C proteinase inhibits viral internal ribosome entry site-mediated translation. J. Virol. 82(19), 9389-9399 (2008).
87. Schwartz M, Chen J, Lee W-M, Janda M, Ahlquist P: Alternate, virus-induced membrane rearrangements support positive-strand RNA virus genome replication. Proc. Natl Acad. Sci. USA 101(31), 11263-11268 (2004).
88. Huang SC, Chang CL, Wang PS, Tsai Y, Liu HS: Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J. Med. Virol. 81(7), 1241-1252 (2009).
89. Jackson WT, Giddings TH Jr, Taylor MP et al.: Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 3(5), e156 (2005).
90. Schlegel A, Giddings TH Jr, Ladinsky MS, Kirkegaard K: Cellular origin and ultrastructure of membranes induced during poliovirus infection. J. Virol. 70(10), 6576-6588 (1996).
91. Steil BP, Barton DJ: Cis-active RNA elements (CREs) and picornavirus RNA replication. Virus Res. 139(2), 240-252 (2009).
92. Richards OC, Spagnolo JF, Lyle JM, Vleck SE, Kuchta RD, Kirkegaard K: Intramolecular and intermolecular uridylylation by poliovirus RNA-dependent RNA polymerase. J. Virol. 80(15), 7405-7415 (2006). (Pubitemid 44092563)
93. Tellez AB, Crowder S, Spagnolo JF et al.: Nucleotide channel of RNA-dependent RNA polymerase used for intermolecular uridylylation of protein primer. J. Mol. Biol. 357(2), 665-675 (2006).
94. Yang Y, Rijnbrand R, Watowich S, Lemon SM: Genetic evidence for an interaction between a picornaviral cis-acting RNA replication element and 3CD protein. J. Biol. Chem. 279(13), 12659-12667 (2004).
95. Gamarnik AV, Andino R: Switch from translation to RNA replication in a positive-stranded RNA virus. Genes Dev. 12(15), 2293-2304 (1998).
96. Gamarnik AV, Andino R: Interactions of viral protein 3CD and poly(rC) binding protein with the 5' untranslated region of the poliovirus genome. J. Virol. 74(5), 2219-2226 (2000).
97. Herold J, Andino R: Poliovirus RNA replication requires genome circularization through a protein-protein bridge. Mol. Cell 7(3), 581-591 (2001).
98. Svitkin YV, Costa-Mattioli M, Herdy B, Perreault S, Sonenberg N: Stimulation of picornavirus replication by the poly(A) tail in a cell-free extract is largely independent of the poly(A) binding protein (PABP). RNA 13(12), 2330-2340 (2007).
99. Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR: Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci. 16(1), 103 (2009).
100. Pettersson RF, Ambros V, Baltimore D: Identification of a protein linked to nascent poliovirus RNA and to the polyuridylic acid of negative-strand RNA. J. Virol. 27(2), 357-365 (1978).
101. Brunner JE, Nguyen JHC, Roehl HH, Ho TV, Swiderek KM, Semler BL: Functional interaction of heterogeneous nuclear ribonucleoprotein C with poliovirus RNA synthesis initiation complexes. J. Virol. 79(6), 3254-3266 (2005).
102. Crowder S, Kirkegaard K: Complete three-dimensional structures of picornaviral RNA-dependent RNA polymerases. Structure 12(8), 1336-1339 (2004).
103. Pathak HB, Ghosh SKB, Roberts AW et al.: Structure-function relationships of the RNA-dependent RNA polymerase from poliovirus (3Dpo1). J. Biol. Chem. 277(35), 31551-31562 (2002).
104. Arnold JJ, Cameron CE: Poliovirus RNA- dependent RNA polymerase (3Dpo1): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+. Biochemistry 43(18), 5126-5137 (2004).
105. Castro C, Arnold JJ, Cameron CE: Incorporation fidelity of the viral RNA- dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 107(2), 141-149 (2005).
106. Pfeiffer JK, Kirkegaard K: Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 1(2), e11 (2005).
107. Pfeiffer JK, Kirkegaard K: A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl Acad. Sci. USA 100(12), 7289-7294 (2003).
108. Vignuzzi M, Wendt E, Andino R: Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14(2), 154-161 (2008).
109. Gohara DW, Arnold JJ, Cameron CE: Poliovirus RNA-dependent RNA polymerase (3Dpo1): kinetic, thermodynamic, and structural analysis of ribonucleotide selection. Biochemistry 43(18), 5149-5158 (2004).
110. Gohara DW, Ha CS, Kumar S et al.: Production of "authentic" poliovirus RNA-dependent RNA polymerase (3Dpo1) by ubiquitin-protease-mediated cleavage in Escherichia coli. Protein Expr. Purif. 17(1), 128-138 (1999).
111. Mestas SP, Sholders AJ, Peersen OB: A fluorescence polarization-based screening assay for nucleic acid polymerase elongation activity. Anal. Biochem. 365(2), 194-200 (2007).
112. Gong P, Campagnola G, Peersen OB: A quantitative stopped-flow fluorescence assay for measuring polymerase elongation rates. Anal. Biochem. 391(1), 45-55 (2009).
113. Lal SK, Kumar P, Yeo WM, Kar-Roy A, Chow VTK: The VP1 protein of human enterovirus 71 self-associates via an interaction domain spanning amino acids 66-297. J. Med. Virol. 78(5), 582-590 (2006).
114. Nugent CI, Kirkegaard K: RNA binding properties of poliovirus subviral particles. J. Virol. 69(1), 13-22 (1995).
115. Pfister T, Pasamontes L, Troxler M, Egger D, Bienz K: Immunocytochemical localization of capsid-related particles in subcellular fractions of poliovirus-infected cells. Virology 188(2), 676-684 (1992).
116. Kuo RL, Kung SH, Hsu YY, Liu WT: Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J. Gen. Virol. 83(6), 1367-1376 (2002).
117. Shih SR, Weng KF, Stollar V, Li ML: Viral protein synthesis is required for enterovirus 71 to induce apoptosis in human glioblastoma cells. J. Neurovirol. 14(1), 53-61 (2008).
118. Li ML, Hsu TA, Chen TC et al.: The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology 293(2), 386-395 (2002).
119. Arita M, Nagata N, Iwata N et al.: An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J. Virol. 81(17), 9386-9395 (2007).
120. Arita M, Shimizu H, Nagata N et al.: Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J. Gen. Virol. 86(5), 1391-1401 (2005).
121. Kung Y-H, Huang S-W, Kuo P-H et al.: Introduction of a strong temperature-sensitive phenotype into enterovirus 71 by altering an amino acid of virus 3D polymerase. Virology 396(1), 1-9 (2010).
122. Wang YF, Chou CT, Lei HY et al.: A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol. 78(15), 7916-7924 (2004).
123. Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY: A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 85(1), 69-77 (2004).
124. Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC: The molecular basis of mouse adaptation by human enterovirus 71. J. Gen. Virol. 89(7), 1622-1632 (2008).
125. Arita M, Ami Y, Wakita T, Shimizu H: Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol. 82(4), 1787-1797 (2008).
126. Shih SR, Stollar V, Lin JY, Chang SC, Chen GW, Li ML: Identification of genes involved in the host response to enterovirus 71 infection. J. Neurovirol. 10(5), 293-304 (2004).
127. Reed LJ, Muench H: A simple method of estimating fifty percent endpoint. Am. J. Hyg. 27, 493-497 (1938).
128. Diamond SE, Kirkegaard K: Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis. J. Virol. 68(2), 863-876 (1994).
129. Gromeier M, Alexander L, Wimmer E: Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl Acad. Sci. USA 93(6), 2370-2375 (1996).
130. Kirkegaard K, Baltimore D: The mechanism of RNA recombination in poliovirus. Cell 47(3), 433-443 (1986).
131. Liu Y, Franco D, Paul AV, Wimmer E: Tyrosine 3 of poliovirus terminal peptide VPg(3B) has an essential function in RNA replication in the context of its precursor protein, 3AB. Virology 81(11), 5669-5684 (2007).
132. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E: Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimisation causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80(19), 9687-9696 (2006).
133. Tung W-H, Hsieh H-L, Yang C-M: Enterovirus 71 induces COX-2 expression via MAPKs, NF-kB, and AP-1 in SK-N-SH cells: role of PGE2 in viral replication. Cell. Signal. 22(2), 234-246 (2010).
134. Leong WF, Chow VTK: Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection. Cell Microbiol. 8(4), 565-580 (2006).
135. Ghukasyan V, Hsu Y-Y, Kung S-H, Kao F-J: Application of fluorescence resonance energy transfer resolved by fluorescence lifetime imaging microscopy for the detection of enterovirus 71 infection in cells. J. Biomed. Opt. 12(2), 024016 (2007).
136. Teterina NL, Levenson EA, Ehrenfeld E: Viable polioviruses that encode 2A proteins with fluorescent protein tags. J. Virol. 84(3), 1477-1488 (2010).
137. Tu PV, Thao NTT, Perera D et al.: Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg. Infect. Dis. 13(11), 1733-1741 (2007).
138. Ministry of Health, Singapore: Surveillance of hand, foot and mouth disease in Singapore. Epidemiol. Bull. 26, 3-5 (2000).
139. Trong-Neng Wu S-FT, Shu-Fang Li et al.: Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg. Infect. Dis. 5, 458-460 (1999).
140. Ong KC, Devi S, Cardosa MJ, Wong KT: Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J. Virol. 84(1), 661-665 (2010).
141. Chung YC, Ho MS, Wu JC et al.: Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26(15), 1855-1862 (2008).
142. Chen HF, Chang MH, Chiang BL, Jeng ST: Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24(15), 2944-2951 (2006).
143. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS: Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20(5-6), 895-904 (2001).
144. Tung W, Bakar S, Sekawi Z, Rosli R: DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 5(1), 6 (2007).
145. Agol VI: Vaccine-derived polioviruses. Biologicals 34(2), 103-108 (2006).
146. Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R: Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4(3), 239-248 (2008).
147. Toyoda H, Yang CF, Takeda N, Nomoto A, Wimmer E: Analysis of RNA synthesis of type 1 poliovirus by using an in vitro molecular genetic approach. J. Virol. 61(9), 2816-2822 (1987).
148. Campbell SA, Lin J, Dobrikova EY, Gromeier M: Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J. Virol. 79(10), 6281-6290 (2005).
149. Rotbart HA, O'Connell JF, McKinlay MA: Treatment of human enterovirus infections. Antiviral Res. 38(1), 1-14 (1998).
150. Pevear DC, Tull TM, Seipel ME, Groarke JM: Activity of Pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43(9), 2109-2115 (1999).
151. Rotbart HA, Webster AD: Treatment of potentially life-threatening enterovirus infections with Pleconaril. Clin. Infect. Dis. 32(2), 228-235 (2001).
152. Starlin R, Reed N, Leeman B, Black J, Trulock E, Mundy LM: Acute flaccid paralysis syndrome associated with echovirus 19, managed with Pleconaril and intravenous immunoglobulin. Clin. Infect. Dis. 33(5), 730-732 (2001).
153. Chen TC, Weng KF, Chang SC, Lin JY, Huang PN, Shih SR: Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 62(6), 1169-1173 (2008).
154. Arita M, Wakita T, Shimizu H: Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J. Gen. Virol. 90(8), 1869-1879 (2009).
155. Crotty S, Maag D, Arnold JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6(12), 1375-1379 (2000).
156. Sim ACN, Luhur A, Tan TMC, Chow VTK, Poh CL: RNA interference against Enterovirus 71 infection. Virology 341(1), 72-79 (2005).
157. Wu Z, Yang F, Zhao R, Zhao L, Guo D, Jin Q: Identification of small interfering RNAs which inhibit the replication of several enterovirus 71 strains in China. J. Virol. Methods 159(2), 233-238 (2009).
158. Tan EL, Tan TMC, Chow VTK, Poh CL: Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol. Ther. 15(11), 1931-1938 (2007).
159. Huang CC: Neurological complications of enterovirus 71 infection in children: lessons from this Taiwan epidemic. Acta Paediatr. Taiwanica 42, 5-7 (2001).
160. Cao R, Han J, Deng Y, Yu M, Qin E, Qin C: Presence of high titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin. Infect. Dis. 50(1), 125-126 (2010).
161. De Breyne S, Yu Y, Unbehaun A, Pestova TV, Hellen CUT: Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc. Natl Acad. Sci. USA 106(23), 9197-9202 (2009).
162. Lin JY, Li ML, Huang PN, Chien KY, Horng JT, Shih SR: Heterogeneous nuclear ribonuclear protein K interacts with the enterovirus 71 5' untranslated region and participates in virus replication. J. Gen. Virol. 89(10), 2540-2549 (2008).
163. Lin JY, Shih SR, Pan M et al.: hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and sindbis virus RNA and is required for viral replication. J. Virol. 83(12), 6106-6114 (2009).
164. Back SH, Kim YK, Kim WJ et al.: Translation of polioviral mRNA is inhibited by cleavage of polypyrimidine tract-binding proteins executed by polioviral 3Cpro. J. Virol. 76(5), 2529-2542 (2002).
165. Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP: Molecular mechanisms of attenuation of the sabin strain of poliovirus type 3. J. Virol. 78(20), 11097-11107 (2004).
166. Florez PM, Sessions OM, Wagner EJ, Gromeier M, Garcia-Blanco M A: The polypyrimidine tract binding protein is required for efficient picornavirus gene expression and propagation. J. Virol. 79(10), 6172-6179 (2005).
167. Song Y, Tzima E, Ochs K et al.: Evidence for an RNA chaperone function of polypyrimidine tract-binding protein in picornavirus translation. RNA 11(12), 1809-1824 (2005).
168. Choi K, Kim JH, Li X et al.: Identification of cellular proteins enhancing activities of internal ribosomal entry sites by competition with oligodeoxynucleotides. Nucl. Acids Res. 32(4), 1308-1317 (2004).
169. Boussadia O, Niepmann M, Creancier L, Prats A-C, Dautry F, Jacquemin-Sablon H: Unr is required in vivo for efficient initiation of translation from the internal ribosome entry sites of both rhinovirus and poliovirus. J. Virol. 77(6), 3353-3359 (2003).
170. Izumi RE, Das S, Barat B, Raychaudhuri S, Dasgupta A: A peptide from autoantigen La blocks poliovirus and hepatitis C virus cap-independent translation and reveals a single tyrosine critical for La RNA binding and translation stimulation. J. Virol. 78(7), 3763-3776 (2004).
171. Shiroki K, Isoyama T, Kuge S et al.: Intracellular redistribution of truncated La protein produced by poliovirus 3Cpro-mediated cleavage. J. Virol. 73(3), 2193-2200 (1999).
172. Hahm B, Kim YK, Kim JH, Kim TY, Jang SK: Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. J. Virol. 72(11), 8782-8788 (1998).
173. Burns CC, Lawson MA, Semler BL, Ehrenfeld E: Effects of mutations in poliovirus 3Dpo1 on RNA polymerase activity and on polyprotein cleavage. J. Virol. 63(11), 4866-4874 (1989).
174. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F: A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J. Virol. 67(8), 4630-4638 (1993).
175. Kean KM, Agut H, Fichot O, Girard M: Substitution in the poliovirus replicase gene determines actinomycin D sensitivity of viral replication at elevated temperature. Virus Res. 12(1), 19-32 (1989).
176. Paul AV, van Boom JH, Filippov D, Wimmer E: Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393(6682), 280-284 (1998).
177. Agut H, Kean KM, Fichot O, Morasco J, Flanegan JB, Girard M: A point mutation in the poliovirus polymerase gene determines a complementable temperature-sensitive defect of RNA replication. Virology 168(2), 302-311 (1989).
178. Gu C, Zeng T, Li Y, Xu Z, Mo Z, Zheng C: Structure-function analysis of mutant RNA-dependent RNA Polymerase complexes with VPg. Biochemistry 74(10), 1132-1141 (2009).
179. ProMed "http://www.promedmail.org"
180. The Free Library: Sinovac developing vaccine for hand, foot, and mouth disease (2008) "http://www.thefreelibrary.com/SINOVAC"SINOVAC DEVELOPING VACCINE FOR HAND, FOOT, AND MOUTH DISEASE-a0187800999